Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 912-918

  Hidaka, M ^a   Iwasaki, S ^b   Matsui, T ^a   Kawakita, T ^a   Inoue, Y ^a   Sakai, T ^a   Harada, N ^a   Takemoto, S ^a   Nagakura, S ^a   Kiyokawa, T ^a   Takahashi, M ^b   Saibara, T ^b   Onishi, S ^b   Kawano, F ^a  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Allo SCT; Bezafibrate; CGVHD; PBC; UDCA

Indexed keywords

ALKALINE PHOSPHATASE; BEZAFIBRATE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FAMOTIDINE; FLUDARABINE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MELPHALAN; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LIVER DISEASE; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL LEUKEMIA; TREATMENT RESPONSE;

ADULT; BEZAFIBRATE; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952421917     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.251     Document Type: Article

References (19)

1. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999;341:14-21.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233.
3. Gilman AL, Serody J. Diagnosis and treatment of chronic graft-versus-host disease. Semin Hematol 2006;43:70-80.
4. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196-1201.
5. Quaglia A, Duarte R, Patch D, Ngianga-Bakwin K, Dhillon AP. Histopathology of graft versus host disease of the liver. Histopathology 2007;50:727-738.
6. Fipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956. (Pubitemid 41754712)
7. Wakae T, Takatsuka H, Seto Y, Iwata N, Mori A, Okada M et al. Similarity between hepatic graft-versus-host disease and primary biliary cirrhosis. Hematology 2002;7:305-310.
8. Quaranta S, Shulman H, Ahmed A, Shoenfeld Y, Peter J, McDonald GB et al. Autoantibodies in human chronic graftversus-host disease after hematopoietic cell transplantation. Clin Immunol 1999;91:106-116.
9. Idilman R, Erden E, Arat M, Soydan E, Erkan O, Kuzu I et al. Trefoil factor expression in biliary epithelium of graft-versushost disease of the liver after allogeneic hematopoietic cell transplantation. Transplantation 2005;80:1099-1104.
10. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-1538.
11. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-1983.
12. Iwasaki S, Akisawa N, Saibara T, Onishi S. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 2007;37(Suppl 3): S515-S517.
13. Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008;38:557-564.
14. Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 1999;16:12-18.
15. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000;95:326-327.
16. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
17. Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou JE. Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. J Pharmacol Exp Ther 2006;317:537-545.
18. De Vree JM, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RP. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000;119:1720-1730.
19. Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006;41:686-692.